Martin Smith - IDEXX Laboratories Ex CTO
| IX1 Stock | EUR 406.20 6.80 1.70% |
Insider
Martin Smith is Ex CTO of IDEXX Laboratories
| Age | 55 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
Martin Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Martin Smith against IDEXX Laboratories stock is an integral part of due diligence when investing in IDEXX Laboratories. Martin Smith insider activity provides valuable insight into whether IDEXX Laboratories is net buyers or sellers over its current business cycle. Note, IDEXX Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell IDEXX Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Martin Smith over two months ago Disposition of tradable shares by Martin Smith of IDEXX Laboratories subject to Rule 16b-3 |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2167 % which means that it generated a profit of $0.2167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.0458 %, meaning that it generated $1.0458 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Amir Khoshniyati | Identiv | N/A | |
| Justin Scarpulla | Identiv | 50 | |
| Steve Dunlap | Identiv | N/A | |
| Eivind Kallevik | Norsk Hydro ASA | 56 | |
| Norman Fitzgerald | NMI Holdings | 56 | |
| Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
| CCLP CMA | Superior Plus Corp | 62 | |
| Wilm Langenbach | Talanx AG | 52 | |
| AnneLene Midseim | Norsk Hydro ASA | 55 | |
| Pal Kildemo | Norsk Hydro ASA | 39 | |
| Sven Pettersson | SIVERS SEMICONDUCTORS AB | 60 | |
| Joakim Weidemanis | Danaher | 54 | |
| JeanJacques Henchoz | Talanx AG | 59 | |
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Edward Kirnbauer | Identiv | 58 | |
| Bernd Sablowsky | Talanx AG | 53 | |
| Manfred Mueller | Identiv | 53 | |
| Rainer Blair | Danaher | 59 | |
| Steven Rales | Danaher | 72 | |
| Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
| Robert Smith | NMI Holdings | 53 | |
Management Performance
| Return On Equity | 1.05 | |||
| Return On Asset | 0.22 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon Underberg, Gen VP | ||
| Ken Grady, VP Officer | ||
| Jonathan Mazelsky, CEO Pres | ||
| Nimrata PE, Ex Operations | ||
| Martin Smith, Ex CTO | ||
| James Polewaczyk, Ex Officer | ||
| Michael Lane, Ex Technology | ||
| John Hart, VP Operations | ||
| Jeffery Chadbourne, Director Reporting | ||
| Brian McKeon, Ex CFO |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.05 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 35.12 B | |||
| Shares Outstanding | 82.9 M | |||
| Shares Owned By Insiders | 0.39 % | |||
| Shares Owned By Institutions | 92.77 % | |||
| Price To Earning | 57.45 X | |||
| Price To Book | 75.09 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in IDEXX Stock
When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.